--- title: "Shuttle Pharmaceuticals Holdings (SHPH) news: delisting" url: "https://aibio.space/companies/shuttle-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SHPH delisting, offering, Nasdaq notice and merger news: Shuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance." --- SHPH Shuttle Pharmaceuticals Holdings, Inc. NASDAQ · United States # Shuttle Pharmaceuticals Holdings (SHPH) news SHPH delisting, offering, Nasdaq notice and merger news Listings · 2026-08-28 ## [Shuttle Pharmaceuticals gets Nasdaq deficiency notice over late Form 10-Q](https://aibio.space/news/shuttle-pharmaceuticals-gets-nasdaq-deficiency-notice-late-form-10/) Nasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026. ## Latest Shuttle Pharmaceuticals Holdings news 1. 2026-05-01 Mergers [Shuttle Pharmaceuticals agrees to merge with United Dogecoin](https://aibio.space/news/shuttle-pharmaceuticals-agrees-merge-united-dogecoin/) The merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026. 2. 2025-11-17 Listings [Shuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance](https://aibio.space/news/shuttle-pharmaceuticals-believes-2-5-million-private-placement/) Shuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report. 3. 2025-03-13 Listings [Shuttle Pharma prices $5.75 million underwritten offering at $0.30 per share](https://aibio.space/news/shuttle-pharma-prices-5-75-million-underwritten-offering-0-30-share/) Shuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis. 4. 2025-02-27 Financings [Shuttle Pharmaceuticals pays Alto $75,000 to waive rights to $10 million of notes](https://aibio.space/news/shuttle-pharmaceuticals-pays-alto-75-000-waive-rights-10-million-notes/) Shuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering. ## Shuttle Pharmaceuticals Holdings at a glance - **Ticker**: SHPH - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $90,238 ### Related companies - [Organon & Co.](https://aibio.space/companies/organon/) NYSE: OGN - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Alumis](https://aibio.space/companies/alumis/) NASDAQ: ALMS - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) NASDAQ: SPRY - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [Petros Pharmaceuticals](https://aibio.space/companies/petros-pharmaceuticals/) OTC: PTPI ### Also on NASDAQ - [MDxHealth SA](https://aibio.space/companies/mdxhealth/) MDXH - [Cerenome](https://aibio.space/companies/cerenome/) CNSY - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) LENZ - [WORK Medical Technology Group LTD](https://aibio.space/companies/work-medical-technology/) WOK - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT - [Nautilus Biotechnology](https://aibio.space/companies/nautilus-biotechnology/) NAUT ## What Shuttle Pharmaceuticals Holdings does Shuttle Pharmaceuticals Holdings, Inc. acquired substantially all of the assets and liabilities of Molecule.ai on November 21, 2025. Molecule.ai is a pharmaceutical software company building an artificial intelligence platform for molecular discovery and early-stage drug development. The platform performs molecular property prediction, cross-molecule and cross-property evaluation, and prediction reasoning that produces structured molecular insights, using transformer-based models and an LLM-based reasoning module. The company is developing a module to evaluate chemical-protein interaction likelihoods, biological context reasoning and an autonomous AI agent designed to plan research steps and route them to the appropriate tools. On November 20, 2025, the company committed to a plan to wind down the clinical trials of Ropidoxuridine, its lead product candidate, and says it is still evaluating the business impacts of that discontinuance and of the Molecule.ai acquisition. Research and development expenses for Ropidoxuridine, before contract reimbursements, were $4,054,831 for fiscal 2025 and $3,618,796 for fiscal 2024. The company had two full-time employees as of the report date. It received Nasdaq notices about its stockholders' equity and minimum bid price, and effected a 1-for-25 reverse stock split on June 16, 2025. | Product or program | What it is | Stage | |---|---|---| | Molecule.ai platform | AI platform for molecular property prediction and structured molecular reasoning | Acquired November 21, 2025; new modules in development | | Autonomous AI agent | Agent to plan research steps, route tasks to tools and iterate on results | In development | | Ropidoxuridine | Lead product candidate whose clinical trials are being wound down | Wind-down of clinical trials committed November 20, 2025 | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/form10-k.htm). ## Shuttle Pharmaceuticals Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | | Net income (loss) | [-$11.7 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | [-$9.1 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | | Cash from operations | [-$9.5 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | [-$7.3 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | | Cash and equivalents | [$334,005](https://www.sec.gov/Archives/edgar/data/1757499/000149315226044107/) | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1757499/000149315226014131/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $90,238. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Shuttle Pharmaceuticals Holdings Was Shuttle Pharmaceuticals Holdings delisted? Our latest story on this, dated Nov 17, 2025: "Shuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/shuttle-pharmaceuticals-believes-2-5-million-private-placement/). Has Shuttle Pharmaceuticals Holdings raised money recently? Our latest story on this, dated May 1, 2026: "Shuttle Pharmaceuticals agrees to merge with United Dogecoin". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/shuttle-pharmaceuticals-agrees-merge-united-dogecoin/). Has Shuttle Pharmaceuticals Holdings received a Nasdaq deficiency notice? Our latest story on this, dated Aug 28, 2026: "Shuttle Pharmaceuticals gets Nasdaq deficiency notice over late Form 10-Q". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/shuttle-pharmaceuticals-gets-nasdaq-deficiency-notice-late-form-10/). Is Shuttle Pharmaceuticals Holdings involved in a merger or acquisition? Our latest story on this, dated May 1, 2026: "Shuttle Pharmaceuticals agrees to merge with United Dogecoin". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/shuttle-pharmaceuticals-agrees-merge-united-dogecoin/). What is the ticker symbol of Shuttle Pharmaceuticals Holdings? Shuttle Pharmaceuticals Holdings, Inc. trades under the ticker SHPH on NASDAQ. Where is Shuttle Pharmaceuticals Holdings listed? Shuttle Pharmaceuticals Holdings, Inc. is listed on NASDAQ. What is the SEC CIK of Shuttle Pharmaceuticals Holdings? The SEC Central Index Key (CIK) for Shuttle Pharmaceuticals Holdings, Inc. is 1757499. Its filings are on SEC EDGAR. How many shares does Shuttle Pharmaceuticals Holdings have outstanding? 4,764,696 shares as of 2026-09-21, per the cover page of its 10-Q filed 2026-09-24. Which country or territory is Shuttle Pharmaceuticals Holdings listed under? Our directory records Shuttle Pharmaceuticals Holdings, Inc. under United States. What does Shuttle Pharmaceuticals Holdings do? Our directory classifies Shuttle Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Shuttle Pharmaceuticals Holdings? The ISIN recorded for Shuttle Pharmaceuticals Holdings, Inc. is US8256935003. Does aibio.space cover Shuttle Pharmaceuticals Holdings? aibio.space lists Shuttle Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Shuttle Pharmaceuticals Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Shuttle Pharmaceuticals Holdings develop? Shuttle Pharmaceuticals Holdings, Inc. acquired substantially all of the assets and liabilities of Molecule.ai on November 21, 2025. Molecule.ai is a pharmaceutical software company building an artificial intelligence platform for molecular discovery and early-stage drug development. What is Molecule.ai platform from Shuttle Pharmaceuticals Holdings? Molecule.ai platform: AI platform for molecular property prediction and structured molecular reasoning Stage: Acquired November 21, 2025; new modules in development. ## Investor discussion: Shuttle Pharmaceuticals Holdings Members talk about Shuttle Pharmaceuticals Holdings (SHPH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Shuttle Pharmaceuticals Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-22 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226048112/form8-k.htm) 2. 2026-09-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226042791/form8-k.htm) 3. 2026-09-01 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226041011/form8-k.htm) 4. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226040622/ex99-1.htm) 5. 2026-08-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226038790/formnt10-q.htm) 6. 2026-08-13 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226037821/formdef14a.htm) 7. 2026-08-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226035855/formpre14a.htm) 8. 2026-06-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226028301/form8-k.htm) 9. 2026-05-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226025340/form8-k.htm) 10. 2026-05-01 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226020830/ex99-1.htm) 11. 2026-04-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226018117/formdef14a.htm) 12. 2026-04-10 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226016212/formpre14a.htm) 13. 2026-02-11 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315226006073/forms-1.htm) 14. 2025-12-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225029361/form8-k.htm) 15. 2025-11-26 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225025082/form8-k.htm) 16. 2025-11-21 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,1.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/form8-k.htm) 17. 2025-11-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225023845/form8-k.htm) 18. 2025-10-21 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225018788/form8-k.htm) 19. 2025-05-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000164117225010964/form8-k.htm) 20. 2025-05-08 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000164117225009325/form10-q.htm) 21. 2025-03-31 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000164117225001889/formdef14a.htm) 22. 2025-03-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225010886/formpre14a.htm) 23. 2025-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225010211/ex99-1.htm) 24. 2025-02-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225008462/form8-k.htm) 25. 2025-02-13 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225006202/forms-1.htm) 26. 2025-01-15 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225002253/forms-1.htm) 27. 2025-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315225001132/ex99-1.htm) 28. 2024-10-31 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1757499/000149315224043154/form424b4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SHPH on TradingView](https://www.tradingview.com/symbols/NASDAQ-SHPH/). ## SEC filings and registration - **SEC name**: Shuttle Pharmaceuticals Holdings, Inc. - **CIK**: 1757499 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SHPH (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 401 PROFESSIONAL DRIVE, GAITHERSBURG, MD, 20879 - **Phone**: (240) 403-4212 - **Shares outstanding**: 4,764,696 as of 2026-09-21 (10-Q filed 2026-09-24) - **Former names**: Shuttle Pharmaceuticals Holdings, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226048112/form8-k.htm) filed 2026-10-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1757499/000149315226044107/form10-q.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226042791/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226042299/form8-k.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226041213/form8-k.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226041011/form8-k.htm) filed 2026-09-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1757499/000149315226040622/form8-k.htm) filed 2026-08-28 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1757499/000149315226037821/formdef14a.htm) filed 2026-08-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001757499), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Shuttle Pharmaceuticals Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SHPH, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Shuttle Pharmaceuticals Holdings, Inc. - **Ticker**: SHPH - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8256935003 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SHPH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/shuttle-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Shuttle Pharmaceuticals Holdings (SHPH) news: delisting", 2026-10-31, https://aibio.space/companies/shuttle-pharmaceuticals/